ESMO 2017

Nivolumab Superior to Ipilimumab for Melanoma Recurrence Prevention

Nivolumab Superior to Ipilimumab for Melanoma Recurrence Prevention

By

The randomized phase 3 CheckMate 238 trial evaluated the safety and efficacy of nivolumab vs ipilimumab in the resected stage III/IV melanoma setting.

Survival Benefit With Pembrolizumab Confirmed in Urothelial Carcinoma

Survival Benefit With Pembrolizumab Confirmed in Urothelial Carcinoma

By

The KEYNOTE-045 trial randomly assigned 542 patients with UC who progressed after 2 or fewer prior therapies to receive pembrolizumab or investigator's choice of paclitaxel, docetaxel, or vinflunine.

Eryaspase May Prolong Overall and Progression-free Survival in Pancreatic Cancer

Eryaspase May Prolong Overall and Progression-free Survival in Pancreatic Cancer

By

Researchers randomly assigned 140 patients with metastatic pancreatic cancer to receive eryaspase with standard of care FOLFOX or chemotherapy alone.

Lenvatinib May Delay Functional Deterioration in Hepatocellular Carcinoma

Lenvatinib May Delay Functional Deterioration in Hepatocellular Carcinoma

By

Patients had similar HRQOL scores by all measures at baseline, but experienced significant changes in scores for the HRQOL domains of Body Image, Diarrhea, Nutrition, Pain, and Role Function.

Osimertinib Shows Promise As A First-line Therapy in EGFRm NSCLC

Osimertinib Shows Promise As A First-line Therapy in EGFRm NSCLC

By

Patients who received osimertinib had a PFS of 18.9 months compared with 10.2 months among those who received SoC treatments (P < .0001).

TILs May Predict Pembrolizumab Response in Triple-negative Breast Cancer

TILs May Predict Pembrolizumab Response in Triple-negative Breast Cancer

By

The results of the study demonstrate that increased TIL levels may be associated with a greater response to pembrolizumab monotherapy in patients with mTNBC, especially in the first-line setting.

Initial Abemaciclib Improves PFS and ORR in Advanced Breast Cancer

Initial Abemaciclib Improves PFS and ORR in Advanced Breast Cancer

By

Researchers compared the efficacy of abemaciclib plus anastrozole or letrozole vs placebo plus anastrozole or letrozole among patients not previously treated with a systemic therapy.

Durvalumab May Prolong PFS in Non-small Cell Lung Cancer After Chemoradiation

Durvalumab May Prolong PFS in Non-small Cell Lung Cancer After Chemoradiation

By

Researchers randomly assigned 713 patients with NSCLC who did not progress after 2 or more cycles of platinum-based concurrent chemoradiation therapy to receive durvalumab 10 mg/kg consolidation therapy or placebo for up to 12 months.

No Difference in Survival With CT Scan at Follow-ups for Resected NSCLC

No Difference in Survival With CT Scan at Follow-ups for Resected NSCLC

By

Although these data did not demonstrate improved survival with the inclusion of a CT scan at routine follow-up visits, the authors noted that a longer follow-up time is necessary to identify any long-term OS benefits.

Liquid Biopsies Are Highly Sensitive for Actionable Mutations in Solid Tumors

Liquid Biopsies Are Highly Sensitive for Actionable Mutations in Solid Tumors

By

Alterations conferring resistance to targeted agents were identified among 18% of samples from NSCLC, breast, colorectal, and prostate cancers, melanoma, and gastrointestinal stromal tumors.

Two Additions to Standard of Care in Prostate Cancer May Improve Outcomes

Two Additions to Standard of Care in Prostate Cancer May Improve Outcomes

By

Long-term hormone monotherapy has been the standard of care for patients with PCa for more than 60 years. The purpose of this study was to compare the efficacy of 2 new treatment standards using a patient subset of the STAMPEDE trial.

FLOT Combination Therapy May Be a New Standard for Esophageal Cancer

FLOT Combination Therapy May Be a New Standard for Esophageal Cancer

By

The relative effects of FLOT were demonstrable in all subgroups, and was pronounced numerically in patients with Barrett tumors, small tumors T1/2, nodal negative tumors, and Siewert type 1 esophageal tumors.

Atezolizumab Improves Overall Survival Regardless of PD-L1 Expression in NSCLC

Atezolizumab Improves Overall Survival Regardless of PD-L1 Expression in NSCLC

By

The phase 3 OAK trial demonstrated that previously treated patients with advanced NSCLC experienced prolonged OS with atezolizumab compared to docetaxel regardless of PD-L1 status.

<i>BRCA2</i> Mutations Associated With Poor Outcomes in mCRPC

BRCA2 Mutations Associated With Poor Outcomes in mCRPC

By

Researchers find BRCA2 mutations are associated with worse outcomes among men with mCRPC.

Similar Efficacy, Less Toxicity with Neoadjuvant Letrozole/Palbociclib Versus Chemo in Breast Cancer

Similar Efficacy, Less Toxicity with Neoadjuvant Letrozole/Palbociclib Versus Chemo in Breast Cancer

By

Although there was less toxicity, neoadjuvant letrozole plus palbociclib had similar response and BCS rates when compared with chemotherapy.

Biosimilar and Reference Rituximab May Have Similar ORR in Follicular Lymphoma

Biosimilar and Reference Rituximab May Have Similar ORR in Follicular Lymphoma

By

Patients with untreated FL were randomly assigned to receive cyclophosphamide, vincristine, and prednisone (CVP) plus rituximab (R) or GP2013 for 8 cycles followed by 2 years of monotherapy maintenance in patients who responded to treatment.

Similar Survival Benefit Observed in Both Simple and Extensive NSCLC Follow-up

Similar Survival Benefit Observed in Both Simple and Extensive NSCLC Follow-up

By

Although guidelines advocate follow-ups consisting of clinic visits and CT-scans, there is a lack of robust data supporting these recommendations.

Neoadjuvant Taselisib Combo Improves ORR in Early ER+/HER2- Breast Cancer

Neoadjuvant Taselisib Combo Improves ORR in Early ER+/HER2- Breast Cancer

By

This trial sought to determine if the letrozole and taselisib combination was effective in early-stage breast cancer.

Cabozantinib and Nivolumab With or Without Ipilimumab May Be Effective in Genitourinary Cancers

Cabozantinib and Nivolumab With or Without Ipilimumab May Be Effective in Genitourinary Cancers

By

Cabozantinib and nivolumab (CaboNivo) with or without ipilimumab (Ipi) demonstrated manageable safety profiles and durable clinical activity.

Adding Pertuzumab Does Not Prolong Overall Survival in HER2+ Gastric or Gastro-esophageal Cancers

Adding Pertuzumab Does Not Prolong Overall Survival in HER2+ Gastric or Gastro-esophageal Cancers

By

Though a longer overall survival was observed in patients who received pertuzumab plus trastuzumab and chemotherapy, it was not statistically significant.

Non-inferiority of Sorafenib-Pazopanib Sequence Not Reached in Renal Cell Carcinoma

Non-inferiority of Sorafenib-Pazopanib Sequence Not Reached in Renal Cell Carcinoma

By

The non-inferiority of the sorafenib (So) and pazopanib (Pa) sequence was not demonstrated compared to pazopanib-sorafenib in patients with metastatic renal cell carcinoma (mRCC).

Nivolumab Plus HPV-16 Vaccine are Promising in HPV-16+ Cancers

Nivolumab Plus HPV-16 Vaccine are Promising in HPV-16+ Cancers

By

Immune checkpoint inhibition may improve the efficacy of vaccine-induced T cells in incurable HPV genotype 16-positive cancer.

Adoptive Cellular Immunotherapy Improves Survival in Resected NSCLC

Adoptive Cellular Immunotherapy Improves Survival in Resected NSCLC

By

Adoptive cellular immunotherapy has not been widely used for cancer treatment.

Benefit of Binimetinib Addition to Encorafenib Confirmed in Melanoma

Benefit of Binimetinib Addition to Encorafenib Confirmed in Melanoma

By

Binimetinib a BRAF inhibitor, improved objective response rate (ORR) and progression-free survival (PFS) among patients with BRAF-mutant melanoma.

Sarcoma Resection at Expert Centers Associated With Better Outcomes

Sarcoma Resection at Expert Centers Associated With Better Outcomes

By

Surgical resection of soft tissue or visceral sarcoma conducted at an expert center resulted in substantially better outcomes compared with nonexpert centers.

Nivolumab plus RT and Temozolomide Tolerated in Glioblastoma

Nivolumab plus RT and Temozolomide Tolerated in Glioblastoma

By

First-line nivolumab plus radiotherapy (RT) with or without temozolomide was tolerated by patients with glioblastoma.

First-Line Dose-Dense Chemo Fails to Prolong PFS in Ovarian Cancer

First-Line Dose-Dense Chemo Fails to Prolong PFS in Ovarian Cancer

By

First-line treatment failed to improve progression-free survival among women of European descent with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC).

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs